NASDAQ:BCRX
BioCryst Pharmaceuticals Stock News
$6.28
-0.190 (-2.94%)
At Close: May 17, 2024
Hereditary Angioedema Patients Report Breakthrough Attacks on Current Injectable/Infused Prophylaxis Medication
07:01am, Saturday, 06'th Jun 2020
BioCryst Pharmaceuticals, Inc. (BCRX) today presented findings from two patient surveys conducted to gain insights into patients’ current hereditary angioedema (HAE) treatment expectations, experie
BioCryst Pharmaceuticals, Inc. (BCRX) today announced new data from the APeX-2 and APeX-S clinical trials, which showed that hereditary angioedema (HAE) patients taking oral, once-daily berotralstat e
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
11:15am, Tuesday, 02'nd Jun 2020
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors granted five newly-hired employees inducement options to purchase an a
RESEARCH TRIANGLE PARK, N.C., June 01, 2020 -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) announced today the completion of an underwritten public offering of 22,044,447.
All the Potential Treatments and Vaccines for COVID-19 | Digital Trends
01:00pm, Saturday, 30'th May 2020
Institutions around the world are working to find treatments and vaccines for COVID-19, the novel coronavirus. The pathway is a long and difficult one.
The
BioCryst to Present at Jefferies Virtual Healthcare Conference
08:15pm, Thursday, 28'th May 2020
RESEARCH TRIANGLE PARK, N.C., May 28, 2020 -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the company will present at the Jefferies Virtual Healthcare.
BioCryst Prices Public Offering of Common Stock and Pre-Funded Warrants
03:35am, Thursday, 28'th May 2020
In addition, and in lieu of common stock, BioCryst is offering to certain investors pre-funded warrants to purchase up to an aggregate of 3,511,111 shares of common stock at a purchase price of $4.49
The Daily Biotech Pulse: PhaseBio To Start Potential Pivotal COVID-19 Trial, Immunomedics CEO Quits, Tetraphase Receives Sweetened Offer
12:00am, Thursday, 28'th May 2020
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs May 27)
ADC Therapeutics SA (NYSE:...
BioCryst Plans to Raise $100 Million
10:21pm, Wednesday, 27'th May 2020
On the cusp of launching berotralstat as a treatment for hereditary angioedema in the U.S. and EU, BioCryst Pharmaceuticals (NASDAQ: BCRX) is planning to sell $100 million of stock in a secondary off
BioCryst Commences Public Offering of Common Stock and Pre-Funded Warrants
08:01pm, Wednesday, 27'th May 2020
BioCryst Pharmaceuticals, Inc. (BCRX) announced today that it is offering to sell $100 million of its common stock and, in lieu of common stock, to offer and sell to certain investors pre-funded war
BioCryst to Present New Berotralstat Data at European Academy of Allergy and Clinical Immunology Digital Congress
11:00am, Tuesday, 26'th May 2020
RESEARCH TRIANGLE PARK, N.C., May 26, 2020 -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the company will present new data on berotralstat (BCX7353), an.
Edited Transcript of BCRX earnings conference call or presentation 6-May-20 12:30pm GMT
04:36am, Tuesday, 26'th May 2020
Q1 2020 BioCryst Pharmaceuticals Inc Earnings Call
BioCryst: Buildup Towards COVID-19 Data, And Some Investment Strategies (NASDAQ:BCRX)
02:07am, Wednesday, 20'th May 2020
This article sets forth various theoretical options strategies for BCRX and analyses which is the best among them. BioCryst stock has shown strong movement in t
Johns Hopkins doctor on Trump's preventative hydroxychloroquine use: 'hopefully other people will not follow this example'
07:18pm, Tuesday, 19'th May 2020
Johns Hopkins Center for Health Security Senior Scholar Dr. Amesh Adalja joins Yahoo Finance’s Seana Smith to discuss President Trump’s remarks that he is taking hydroxychloroquine as a preventati
